Dong-Yu Wang

List of Publications by Year
in descending order

36	1,198	430874 18	377865 34
papers	citations	h-index	g-index

36	36	36	2103
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy. Nature Communications, 2020, 11, 1825.	12.8	21
2	Stratifying the stratifiers of triple negative breast cancer. Oncotarget, 2020, 11, 306-308.	1.8	1
3	A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. Breast Cancer Research, 2019, 21, 18.	5.0	37
4	Molecular stratification within triple-negative breast cancer subtypes. Scientific Reports, 2019, 9, 19107.	3.3	78
5	Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer. Cell Reports, 2018, 23, 112-126.	6.4	58
6	CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead. Molecular and Cellular Oncology, 2018, 5, e1481814.	0.7	9
7	Mapping genomic and transcriptomic alterations spatially in epithelial cells adjacent to human breast carcinoma. Nature Communications, 2017, 8, 1245.	12.8	14
8	microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer. JCI Insight, 2017, 2, .	5.0	22
9	Kruppel-like factor 6 suppresses growth and invasion of hepatocellular carcinoma cells in vitro and in vivo. International Journal of Immunopathology and Pharmacology, 2016, 29, 666-675.	2.1	10
10	Common and distinct features of mammary tumors driven by Pten-deletion or activating Pik3ca mutation. Oncotarget, 2016, 7, 9060-9068.	1.8	11
11	Combined deletion of <scp>P</scp>ten and p53 in mammary epithelium accelerates tripleâ€negative breast cancer with dependency on e<scp>EF</scp>2<scp>K</scp>. EMBO Molecular Medicine, 2014, 6, 1542-1560.	6.9	91
12	Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations. Breast Cancer Research, 2014, 16, R71.	5.0	8
13	Abstract 5116: The calcium channel subunit CACNG4 plays a role in breast cancer metastasis.. Cancer Research, 2013, 73, 5116-5116.	0.9	1
14	Lunatic Fringe Deficiency Cooperates with the Met/Caveolin Gene Amplicon to Induce Basal-like Breast Cancer. Cancer Cell, 2012, 21, 626-641.	16.8	113
15	A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis. Breast Cancer Research, 2011, 13, R92.	5.0	20
16	Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation. Breast Cancer Research and Treatment, 2011, 129, 373-386.	2.5	26
17	Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens. BMC Cancer, 2011, 11, 253:1-13.	2.6	28
18	Troglitazone suppresses telomerase activity independently of PPARÎ³ in estrogen-receptor negative breast cancer cells. BMC Cancer, 2010, 10, 390.	2.6	18

#	Article	IF	Citations
19	The effects of timing of fine needle aspiration biopsies on gene expression profiles in breast cancers. BMC Cancer, 2008, 8, 277.	2.6	13
20	Identification of Estrogen-Responsive Genes by Complementary Deoxyribonucleic Acid Microarray and Characterization of a Novel Early Estrogen-Induced Gene:EEIG1. Molecular Endocrinology, 2004, 18, 402-411.	3.7	129
21	Gene Expression Profiles for Detecting and Distinguishing Potential Endocrine-Disrupting Compounds in Environmental Samples. Environmental Science & Technology, 2004, 38, 6396-6406.	10.0	25
22	DNA microarrays for detecting endocrine-disrupting compounds. Biotechnology Advances, 2003, 22, 17-26.	11.7	15
23	CASE REPORT: Hepatocellular carcinoma in type 1a glycogen storage disease with identification of a glucose-6-phosphatase gene mutation in one family. Journal of Gastroenterology and Hepatology (Australia), 2002, 14, 553-558.	2.8	13
24	MDM2 Overexpression with Alteration of the p53 Protein and Gene Status in Oral Carcinogenesis. Japanese Journal of Cancer Research, 2000, 91, 492-498.	1.7	6
25	Mxi1 is a potential cellular target of carcinogens and frequently mutated in experimental rat tumors and tumor cell lines. Pathology International, 2000, 50, 373-383.	1.3	11
26	Isolation and Localization of Type IIb Na/Pi Cotransporter in the Developing Rat Lung. American Journal of Pathology, 2000, 157, 21-27.	3.8	59
27	Mxi1Mutations in Human Neurofibrosarcomas. Japanese Journal of Cancer Research, 1999, 90, 740-746.	1.7	16
28	Î±PIX nucleotide exchange factor is activated by interaction with phosphatidylinositol 3-kinase. Oncogene, 1999, 18, 5680-5690.	5.9	99
29	Mutational Analyses of Multiple Target Genes in Histologically Heterogeneous Gastric Cancer with Microsatellite Instability. Japanese Journal of Cancer Research, 1998, 89, 1284-1291.	1.7	14
30	Interaction of EphB2-tyrosine kinase receptor and its ligand conveys dorsalization signal in Xenopus laevis development. Oncogene, 1998, 17, 1509-1516.	5.9	18
31	Expression of high-mobility group-1 mRNA in human gastrointestinal adenocarcinoma and corresponding non-cancerous mucosa. International Journal of Cancer, 1997, 74, 1-6.	5.1	52
32	Expression of structure-specific recognition protein mRNA in fetal kidney and Fe-nitrilotriacetate-induced renal carcinoma in the rat. Cancer Letters, 1996, 106, 271-278.	7.2	10
33	Identification of cytokeratin subspecies altered in rat experimental esophageal tumors by subtractive cloning. Cancer Letters, 1996, 108, 119-127.	7.2	3
34	Efficient and specific induction of esophageal tumors in rats by precursors of Nâ€nitrososarcosine ethyl ester. Pathology International, 1995, 45, 415-421.	1.3	10
35	High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer, 1994, 74, 3089-3096.	4.1	79
36	Cytologic screening for esophageal cancer: Results from 12,877 subjects from a high-risk population in China. International Journal of Cancer, 1993, 54, 185-188.	5.1	60